Led by NYU Langone Health Department of Orthopedic Surgery researchers, the study included training a computer system to help analyze animal cells damaged by increasing concentrations of chemicals over time to replicate human aging.

The goal of this new agreement is to help CorNav more effectively develop the means to address this important unmet need and improve the epicardial treatment of VT that afflicts millions of people in the United States and around the world, explains James Fonger, M.D., founder and CEO.

The grant will help City of Hope create a bio map of tumor changes that cause immunotherapy resistance in advanced or metastatic non-small cell lung cancer.